Peking University People's Hospital
Beijing, 100044, China
NCT Number: NCT02412423
In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 4
Beijing, 100044, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: participants will be followed for an expected average of 365 days
Time frame: participants will be followed for an expected average of 365 days
Time frame: participants will be followed for an expected average of 365 days
Time frame: participants will be followed for an expected average of 365 days
Peking University People's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06904053
Hematopoietic Stem Cell Transplantation
Bethesda, Maryland, United States
View Trial DetailsNCT04635397
Hematopoietic Stem Cell Transplantation
Nice, CHU de NICE, France
View Trial DetailsNCT03803696
Genital Diseases, Hematologic Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT02763033
Hematopoietic Stem Cell Transplantation
Ann Arbor, Michigan, United States
View Trial Details